

Vaccinia Virus, Modified Vaccinia Ankara (MVA)

Catalog No. NR-1

For research use only. Not for use in humans.

Contributor:

National Institute of Allergy and Infectious Diseases (NIAID),
National Institutes of Health (NIH)

Manufacturer:

BEI Resources

Product Description:

Virus Classification: *Poxviridae, Orthopoxvirus*

Species: Vaccinia Virus (VACV)

Strain/Isolate: Modified VACV Ankara (MVA)

Original Source: The early passage history of MVA is complex.¹

Comments: The complete genomic sequence of MVA has been determined (GenBank: [U94848](#)).²

MVA is a highly attenuated strain of vaccinia virus and does not appear to replicate in most mammalian cells.³

Material Provided:

Each vial contains approximately 1.0 mL of cell lysate and supernatant from SL-29 chicken embryo fibroblast (CEF; ATCC® CRL-1590™) cells infected with VACV, MVA.

Note: If homogeneity is required for your intended use, please purify prior to initiating work.

Packaging/Storage:

NR-1 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Growth Conditions:

Host: Chicken embryo fibroblast (SL-29 CEF) cells (ATCC® CRL-1590™)

Growth Medium: Dulbecco's Modified Eagle's Medium with 5% fetal bovine serum and 5% tryptose phosphate broth, or equivalents

Infection: Cells should be 80% to 90% confluent

Incubation: 3 to 5 days at 37°C and 5% CO₂

Cytopathic Effect: Cell rounding and sloughing

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Vaccinia Virus, Modified Vaccinia Ankara (MVA), NR-1."

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services,

Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. [Biosafety in Microbiological and Biomedical Laboratories \(BMBL\)](#). 6th ed. Washington, DC: U.S. Government Printing Office, 2020.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Mayr, A., V. Hochstein-Mintzel, and H. Stickl. "Passage History, Properties, and Applicability of the Attenuated Vaccinia Virus Strain MVA." *Infection* 3 (1975): 6-14.
2. Antoine, G., F. Scheiflinger, F. Dorner, and F. G. Falkner. "The Complete Genomic Sequence of the Modified Vaccinia Ankara Strain: Comparison with Other Orthopoxviruses." *Virology* 244 (1998): 365-396. PubMed: 9601507. GenBank: U94848..
3. Wyatt, L. S., et al. "Marker Rescue of the Host Range Restriction Defects of Modified Vaccinia Virus Ankara." *Virology* 251 (1998): 334-342. PubMed: 9837798.

ATCC® is a trademark of the American Type Culture Collection.

